Risk of Permanent Hypoparathyroidism Requiring Calcitriol Therapy in a Population-Based Cohort of Adults Older Than 65 Undergoing Total Thyroidectomy for Graves' Disease
Authors' conclusion
The risk of permanent hypoparathyroidism requiring calcitriol therapy among this national, U.S. population-based cohort of older adults with GD treated with total thyroidectomy was low, even when considering operations performed by a heterogeneous group of surgeons.
Study context
- Population
- Medicare beneficiaries older than 65 years with Graves' disease (GD) who underwent total thyroidectomy, 2007–2017, US; excluded preoperative thyroid cancer or long-term preoperative calcitriol
- Participants
- 4,650 participants
- Outcome
- Permanent hypoparathyroidism: persistent calcitriol use between 6 and 12 months after thyroidectomy
- Follow-up
- 6–12 months after thyroidectomy
Methodological details100% Medicare claims, multivariable logistic regression
- 100% Medicare claims
- Multivariable logistic regression
Main finding
As reported in the abstract
Permanent hypoparathyroidism requiring calcitriol therapy
Patients with permanent hypoparathyroidism
104 (2.2% [95% CI 1.8-2.7%])
Observational data: associations, not effects.
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| Characteristics associated with permanent hypoparathyroidismAge ≥76 yearsvs Age 66-75 years | 1.68 (1.13–2.51) | |
| 0.20.5125Odds ratio (log scale) |
- Characteristics associated with permanent hypoparathyroidism — Mean age, permanent hypoparathyroidism vs none (p = 0.04)
- 74.1 vs. 72.8 years
- Characteristics associated with permanent hypoparathyroidism: multivariable regression; older age the only associated characteristic
Original publication
Risk of Permanent Hypoparathyroidism Requiring Calcitriol Therapy in a Population-Based Cohort of Adults Older Than 65 Undergoing Total Thyroidectomy for Graves' Disease. Thyroid. Published 15 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →